Prenatal Screening - The First Look
- First Trimester (11-13+6 wks): Combined test is standard.
- Biochemical: ↑ free β-hCG, ↓ PAPP-A.
- USG: ↑ Nuchal Translucency (NT).
- Second Trimester (15-20 wks): Quadruple test.
- Markers: ↓ AFP, ↑ β-hCG, ↓ uE3, ↑ Inhibin A.
- NIPS/NIPT: Non-invasive prenatal screening/testing. Highest detection rate for aneuploidies.
⭐ In Down Syndrome, all markers in the second-trimester screen are down except for hCG and Inhibin A, which are high.

1st Trimester Screening - The Early Birds
- When: 11-14 weeks gestation (or CRL 45-84 mm).
- What: A combined screening test for aneuploidies (Trisomy 21, 18, 13).
- Components:
- Biochemical Markers (Double Marker Test):
- ↓ PAPP-A (Pregnancy-Associated Plasma Protein-A)
- ↑ Free β-hCG (human chorionic gonadotropin)
- Sonographic Markers (NT Scan):
- ↑ Nuchal Translucency (NT)
- Absent/Hypoplastic Nasal Bone
- Biochemical Markers (Double Marker Test):

⭐ The combined test boasts a detection rate of ~85% for Down Syndrome. It is a screening test; positive results require diagnostic confirmation (e.g., CVS or amniocentesis).
2nd Trimester Screening - The Mid-Game Scan
- Timing: 15-20 weeks (ideal: 16-18 weeks).
- Tests: Ultrasound (for anomalies) + Maternal serum screening.
- Quadruple Test: Measures 4 markers:
- Alpha-fetoprotein (AFP)
- Human chorionic gonadotropin (hCG)
- Unconjugated estriol (uE3)
- Inhibin A

⭐ The Quadruple test has a detection rate of approximately 80% for Down syndrome.
Invasive Diagnostic Tests - The Decisive Divers
- Definitive diagnosis for chromosomal/genetic disorders. Involves sampling fetal tissue/fluid, each with specific timing and risks.
| Test | Gestational Age (GA) | Risk of Fetal Loss | Key Points |
|---|---|---|---|
| Chorionic Villus Sampling (CVS) | 10-13 wks | ~1% | Earliest test. Cannot detect NTDs. |
| Amniocentesis | 15-20 wks | ~0.5% | Can detect NTDs (↑AFP). |
| Cordocentesis (PUBS) | >18 wks | 1-2% | Rapid karyotype; fetal therapy. |
NIPT & Beyond - The DNA Detective
- Non-Invasive Prenatal Testing (NIPT): Analyzes cell-free fetal DNA (cffDNA) from maternal plasma.
- Performed from 10 weeks gestation onwards.
- Screens for common aneuploidies (Trisomy 21, 18, 13) & sex chromosome abnormalities.
- High detection rate for Down syndrome (>99%).
- Confirmatory Tests: NIPT is a screening tool; positive results require confirmation via Chorionic Villus Sampling (CVS) or Amniocentesis.
⭐ Fetal Fraction: The proportion of cffDNA in maternal blood. A level <4% is a major cause of NIPT failure or false-negative results.
High‑Yield Points - ⚡ Biggest Takeaways
- Nuchal Translucency (NT) is the most important first-trimester ultrasound marker for Down syndrome.
- The double marker test (PAPP-A, β-hCG) is the key first-trimester biochemical screen.
- The quadruple screen (AFP, hCG, estriol, inhibin A) is the standard second-trimester biochemical test.
- Amniocentesis (15-20 weeks) and Chorionic Villus Sampling (CVS) (10-13 weeks) are the primary invasive diagnostic tests.
- Cell-free fetal DNA (cffDNA) is the most sensitive non-invasive screening test for aneuploidy.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app